Oncorus (NASDAQ:ONCR) Upgraded to “Hold” at Zacks Investment Research

Oncorus (NASDAQ:ONCRGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks.com reports.

According to Zacks, “Oncorus Inc. is a clinical stage biopharmaceutical company. It is focused on developing viral immunotherapies to transform outcomes for cancer patients. The company’s product candidate includes ONCR-177, which is in clinical stage. Oncorus Inc. is based in CAMBRIDGE, Mass. “

A number of other brokerages have also weighed in on ONCR. Maxim Group lowered their target price on Oncorus from $20.00 to $7.00 in a research note on Thursday, March 10th. HC Wainwright began coverage on Oncorus in a research report on Monday, March 28th. They issued a “buy” rating and a $7.00 price objective for the company.

Shares of NASDAQ:ONCR opened at $1.25 on Thursday. Oncorus has a twelve month low of $1.15 and a twelve month high of $17.79. The firm has a market cap of $32.36 million, a PE ratio of -0.49 and a beta of 4.26. The business has a fifty day moving average of $1.62 and a 200-day moving average of $4.32.

Oncorus (NASDAQ:ONCRGet Rating) last announced its earnings results on Wednesday, May 4th. The company reported ($0.69) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.77) by $0.08. On average, analysts predict that Oncorus will post -2.83 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in ONCR. SG Americas Securities LLC increased its position in Oncorus by 39.5% in the third quarter. SG Americas Securities LLC now owns 47,851 shares of the company’s stock worth $447,000 after purchasing an additional 13,541 shares during the period. Prosight Management LP grew its position in shares of Oncorus by 10.8% during the 3rd quarter. Prosight Management LP now owns 55,411 shares of the company’s stock worth $518,000 after buying an additional 5,411 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Oncorus during the 3rd quarter worth about $281,000. Trexquant Investment LP grew its position in shares of Oncorus by 84.5% during the 3rd quarter. Trexquant Investment LP now owns 26,028 shares of the company’s stock worth $243,000 after buying an additional 11,919 shares during the period. Finally, Sectoral Asset Management Inc grew its position in shares of Oncorus by 8.0% during the 3rd quarter. Sectoral Asset Management Inc now owns 361,821 shares of the company’s stock worth $3,379,000 after buying an additional 26,821 shares during the period. Hedge funds and other institutional investors own 84.26% of the company’s stock.

About Oncorus (Get Rating)

Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.

Read More

Get a free copy of the Zacks research report on Oncorus (ONCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.